{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.5","upperLimit":"73.7","value":"65.5"}]}],"title":"3-year EFS Estimate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.8","upperLimit":"62.3","value":"53.1"}]}],"title":"5-year EFS Estimate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"Overall estimation of the EFS of dasatinib plus chemotherapy was performed utilizing the Kaplan-Meier (KM) Product Limit method. The 3-year and 5-year EFS rates were computed with the corresponding 95% CI's using Greenwood's formula. Analyses of EFS included KM plots with number of patients at risk. Participants who neither relapse nor die or who are lost to follow-up were censored on the date of their last bone marrow, CSF assessment or physical exam, whichever occurred last.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents newly diagnosed with Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL) treated with standard multiagent chemotherapy and Dasatinib (either in tablets or Powder For Oral Suspension (PFOS)) at a dose of 60 mg/m2 daily.","id":"OG000","title":"Dasatinib Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to 3 years or 5 years following first dose","title":"Event-Free Survival (EFS) Rate (Kaplan-Meier Estimates)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}